{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:05:49Z","timestamp":1789725949764,"version":"4.0.1"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018609","name":"Shenzhen High-level Hospital Construction Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018609","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Discipline Construction Hospital Supporting Fund"},{"name":"Third People\u2019s Hospital of Shenzhen","award":["XKJS-2025011"],"award-info":[{"award-number":["XKJS-2025011"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study aimed to assess the incidence and clinical characteristics of active tuberculosis (ATB) in cancer patients treated with immune checkpoint inhibitors (ICIs) to inform optimal ICI utilization strategies in TB-endemic areas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective analysis of 889 consecutive cancer patients who received at least one cycle of ICIs at The Third People's Hospital of Shenzhen between 01\/01\/2018 and 31\/12\/2024. Patients who developed ATB following ICI initiation were identified, and their demographic data, tumor type, ICI regimen, medical history, body mass index (BMI), and TB characteristics (time of occurrence, site) were systematically evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 889 patients, the median follow-up duration was 19 months (IQR 9.7\u201332 months). The total follow-up time for the entire cohort was 1634.1 person-years. Forty-four patients developed ATB. The TB incidence rate was 2693 per 100 000 person-years (95% CI: 1956\u20133607). A total of 169 patients died during follow-up and 20 were lost to follow-up; data for both groups were censored at the last known contact date. All affected patients were male, with a median age of 61 years and a median BMI of 18.1\u2005kg\/m2. Lung cancer is an independent risk factor for ATB associated with ICIs. The median time to ATB onset after ICI initiation was 7.1 months, and patients had received a median of 5 ICI treatment cycles prior to TB diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This single-center retrospective cohort from a high TB-burden region demonstrated an observed TB incidence of 2693 cases per 100 000 person-years, which is higher than the general population incidence in China (55 per 100 000). While this observation cannot establish a causal relationship between ICIs and TB, it suggests that TB screening and monitoring protocols may warrant consideration in similar clinical settings. Prospective controlled studies are needed to confirm the attributable TB risk associated with ICI therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag517","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T11:48:43Z","timestamp":1786535323000},"source":"Crossref","is-referenced-by-count":0,"title":["Immune Checkpoint Inhibitors in Cancer Patients With Concurrent Active Tuberculosis: A Real-World Study in a High Tuberculosis Burden Region"],"prefix":"10.1093","volume":"13","author":[{"given":"Xunqi","family":"Liu","sequence":"first","affiliation":[{"name":"The Third People\u2019s Hospital of Shenzhen, Second Affiliated Hospital of Southern University of Science and Technology Department of Medical Oncology, , Shenzhen, Guangdong Province ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Cai","sequence":"additional","affiliation":[{"name":"The Third People\u2019s Hospital of Shenzhen, Second Affiliated Hospital of Southern University of Science and Technology Department of Medical Oncology, , Shenzhen, Guangdong Province ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Shao","sequence":"additional","affiliation":[{"name":"The Third People\u2019s Hospital of Shenzhen, Second Affiliated Hospital of Southern University of Science and Technology Department of Medical Oncology, , Shenzhen, Guangdong Province ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6774-6868","authenticated-orcid":false,"given":"Hu","family":"Liu","sequence":"additional","affiliation":[{"name":"The Third People\u2019s Hospital of Shenzhen, Second Affiliated Hospital of Southern University of Science and Technology Department of Medical Oncology, , Shenzhen, Guangdong Province ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianghong","family":"An","sequence":"additional","affiliation":[{"name":"The Third People\u2019s Hospital of Shenzhen, Second Affiliated Hospital of Southern University of Science and Technology Department of Medical Oncology, , Shenzhen, Guangdong Province ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"2026091805322705300_ofag517-B1","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/s41571-025-01061-7","article-title":"Treatment of NSCLC after chemoimmunotherapy\u2014are we making headway?","volume":"22","author":"Reck","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"2026091805322705300_ofag517-B2","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"key":"2026091805322705300_ofag517-B3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13045-024-01578-x","article-title":"Recent developments in immunotherapy for gastrointestinal tract cancers","volume":"17","author":"Chong","year":"2024","journal-title":"J Hematol Oncol"},{"key":"2026091805322705300_ofag517-B4","doi-asserted-by":"crossref","first-page":"105853","DOI":"10.1016\/j.rmed.2019.105853","article-title":"Development of tuberculosis in cancer patients receiving immune checkpoint inhibitors","volume":"161","author":"Im","year":"2020","journal-title":"Respir Med"},{"key":"2026091805322705300_ofag517-B5","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.lungcan.2020.05.020","article-title":"Immune checkpoint inhibition for non-small cell lung cancer in patients with pulmonary tuberculosis or hepatitis B: experience from a single Asian centre","volume":"146","author":"Chan","year":"2020","journal-title":"Lung Cancer"},{"key":"2026091805322705300_ofag517-B6","first-page":"779","article-title":"China liver cancer guidelines for the diagnosis and treatment of hepatocellular carcinoma (2024 edition)","volume":"14","author":"Zhou","year":"2025","journal-title":"Liver Cancer"},{"key":"2026091805322705300_ofag517-B7","first-page":"59","article-title":"Diagnostic criteria for tuberculosis (WS 288\u20142017)","volume":"3","author":"People's Republic of China state health and Family Planning Commission","year":"2018","journal-title":"Elect J Emerg Infect Dis"},{"key":"2026091805322705300_ofag517-B8","doi-asserted-by":"crossref","DOI":"10.2196\/57209","article-title":"Pulmonary Tuberculosis notification rate within Shenzhen, China, 2010-2019: spatial-temporal analysis","volume":"10","author":"Lai","year":"2024","journal-title":"JMIR Public Health Surveill"},{"issue":"null","key":"2026091805322705300_ofag517-B9","doi-asserted-by":"crossref","first-page":"107325","DOI":"10.1016\/j.ijid.2024.107325","article-title":"Insights from the 2024 WHO global Tuberculosis report \u2013 more comprehensive action, innovation, and investments required for achieving WHO End TB goals","volume":"150","author":"Goletti","year":"2025","journal-title":"Int J Infect Dis"},{"key":"2026091805322705300_ofag517-B10","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa126","article-title":"Incidence of active Tuberculosis in lung cancer patients receiving immune checkpoint inhibitors","volume":"7","author":"Fujita","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2026091805322705300_ofag517-B11","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.lungcan.2021.05.034","article-title":"Incidence of tuberculosis in advanced lung cancer patients treated with immune checkpoint inhibitors - A nationwide population-based cohort study","volume":"158","author":"Kim","year":"2021","journal-title":"Lung Cancer"},{"key":"2026091805322705300_ofag517-B12","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1164\/rccm.201807-1250LE","article-title":"Implications of Tuberculosis reactivation after immune checkpoint inhibition","volume":"198","author":"Elkington","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2026091805322705300_ofag517-B13","first-page":"102213","article-title":"Immune reconstitution inflammatory syndrome (IRIS): case series and review of the literature","volume":"55","author":"Schregenberger","year":"2025","journal-title":"Respir Med Case Rep"},{"key":"2026091805322705300_ofag517-B14","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abf3861","article-title":"PD-1 blockade exacerbates Mycobacterium tuberculosis infection in rhesus macaques","volume":"6","author":"Kauffman","year":"2021","journal-title":"Sci Immunol"},{"key":"2026091805322705300_ofag517-B15","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1002\/cam4.2868","article-title":"PD-1 inhibitors for non-small cell lung cancer patients with special issues: real-world evidence","volume":"9","author":"Byeon","year":"2020","journal-title":"Cancer Med"},{"key":"2026091805322705300_ofag517-B16","doi-asserted-by":"crossref","first-page":"640903","DOI":"10.3389\/fimmu.2021.640903","article-title":"Male sex bias in immune biomarkers for Tuberculosis","volume":"12","author":"Bothamley","year":"2021","journal-title":"Front Immunol"},{"key":"2026091805322705300_ofag517-B17","article-title":"Extracellular delivery of functional mitochondria rescues the dysfunction of CD4+ T cells in aging","volume":"11","author":"Headley","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"2026091805322705300_ofag517-B18","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.cmi.2017.12.003","article-title":"Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment","volume":"24","author":"Picchi","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2026091805322705300_ofag517-B19","doi-asserted-by":"crossref","first-page":"101959","DOI":"10.1016\/j.smim.2025.101959","article-title":"Immune dysregulation of diabetes in tuberculosis","volume":"78","author":"Thong","year":"2025","journal-title":"Semin Immunol"},{"key":"2026091805322705300_ofag517-B20","doi-asserted-by":"crossref","first-page":"30474","DOI":"10.1038\/s41598-025-16385-8","article-title":"Metabolic dysfunction impairs Mycobacterium tuberculosis-specific cytokine and chemokine responses in latent tuberculosis and type 2 diabetes mellitus","volume":"15","author":"Ssekamatte","year":"2025","journal-title":"Sci Rep"},{"key":"2026091805322705300_ofag517-B21","article-title":"Coexisting lung cancer and pulmonary Tuberculosis: a comprehensive review from incidence to management","volume":"8","author":"Zhou","year":"2025","journal-title":"Cancer Rep (Hoboken)"},{"key":"2026091805322705300_ofag517-B22","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1162190","article-title":"Tuberculosis infection following immune checkpoint inhibitor treatment for advanced cancer: a case report and literature review","volume":"14","author":"Lin","year":"2023","journal-title":"Front Immunol"},{"key":"2026091805322705300_ofag517-B23","article-title":"Tuberculosis infection in patients with rheumatic diseases under different treatments","volume":"18","author":"Liu","year":"2025","journal-title":"J Infect Public Heal"},{"key":"2026091805322705300_ofag517-B24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14740338.2025.2486309","article-title":"Infection toxicity assessment of tumor necrosis factor \u03b1 inhibitors in the treatment of IBD: a real-world study based on the US food and drug administration adverse events reporting system (FAERS)","author":"Cheng","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"2026091805322705300_ofag517-B25","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1473-3099(21)00261-9","article-title":"The diagnostic performance of novel skin-based in-vivo tests for tuberculosis infection compared with purified protein derivative tuberculin skin tests and blood-based in vitro interferon-\u03b3 release assays: a systematic review and meta-analysis","volume":"22","author":"Krutikov","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2026091805322705300_ofag517-B26","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.cmi.2023.07.003","article-title":"Risk of progression to active tuberculosis for indeterminate interferon-gamma release assay in immunocompromised individuals: a systematic review and meta-analysis","volume":"29","author":"Zhou","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"2026091805322705300_ofag517-B27","doi-asserted-by":"crossref","first-page":"109132","DOI":"10.1016\/j.clim.2022.109132","article-title":"Positive rates of interferon-\u03b3 release assay and tuberculin skin test in detection of latent tuberculosis infection: a systematic review and meta-analysis of 200,000 head-to-head comparative tests","volume":"245","author":"Zhou","year":"2022","journal-title":"Clin Immunol"},{"key":"2026091805322705300_ofag517-B28","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1007\/s00262-021-02905-8","article-title":"Active and latent tuberculosis infections in patients treated with immune checkpoint inhibitors in a non-endemic tuberculosis area","volume":"70","author":"Stroh","year":"2021","journal-title":"Cancer Immunol Immun"},{"key":"2026091805322705300_ofag517-B29","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1007\/s00262-022-03198-1","article-title":"Serial interferon-gamma release assay in lung cancer patients receiving immune checkpoint inhibitors: a prospective cohort study","volume":"71","author":"Fujita","year":"2022","journal-title":"Cancer Immunol Immunother"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag517\/70730662\/ofag517.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/9\/ofag517\/70730662\/ofag517.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/9\/ofag517\/70730662\/ofag517.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:33:13Z","timestamp":1789723993000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag517\/8767468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag517","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,8,21]]},"article-number":"ofag517"}}